Risperdal Consta (risperidone microspheres)

**Override(s)** | Approval Duration
--- | ---
Prior Authorization | 1 year
Quantity Limit | 1 year

**Medications** | Quantity Limit
--- | ---
Risperdal Consta (risperidone microspheres) | May be subject to quantity limits

**APPROVAL CRITERIA**

Requests for Risperdal Consta (risperidone microspheres) may be approved if the following criteria are met:

1. Individual is 18 years of age or older; **AND**
2. Individual is using for the treatment of Schizophrenia; **AND**
3. Individual has demonstrated tolerability with oral risperidone;

**OR**

4. Individual is 18 years of age or older; **AND**
5. Individual is using for the maintenance treatment of Bipolar I Disorder; **AND**
6. Individual has demonstrated tolerability with oral risperidone; **AND**
7. Individual is using in one of the following treatment regimens:
   a. As monotherapy; **OR**
   b. As adjunctive therapy to lithium or valproate.

**Note:** Risperdal Consta (risperidone microspheres) has a black box warning regarding use in elderly individuals with dementia-related psychosis. Such individuals are at an increased risk of death; therefore, Risperdal Consta is not approved for the treatment of dementia-related psychosis. It is recommended that responding individuals be continued on treatment with Risperdal Consta at the lowest dose needed. The physician who elects to use Risperdal Consta for extended periods should periodically re-evaluate the long-term risks and benefits of the drug for each individual. Risperdal Consta is a long-acting injection and is a combination of extended-release microspheres for injection and diluent for parenteral use.
This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

WEB-PEC-0511-16